MediWound Ltd. (NASDAQ: MDWD) has received an additional $3.3 million from the U.S. Department of War to develop a room-temperature-stable formulation of its NexoBrid® product, according to a company statement.

The supplemental award brings the total program budget to $21.8 million. The funding is non-dilutive and is intended to support development through the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration.

NexoBrid is an FDA-approved biologic used for the enzymatic removal of eschar in thermal burns. The room-temperature-stable formulation is being developed as a non-surgical debridement option for battlefield burn care, where cold-chain storage and surgical facilities may not be available.

Chief Executive Officer Ofer Gonen said the company's focus is on "completing CMC development, establishing in-house cGMP manufacturing capabilities, and producing clinical batches to support the clinical program."

The development program falls within the scope of MediWound's existing North American license agreement with Vericel Corporation (NASDAQ: VCEL), which holds exclusive commercial and development rights to NexoBrid in North America.